lonafarnib has been researched along with temozolomide in 5 studies
| Studies (lonafarnib) | Trials (lonafarnib) | Recent Studies (post-2010) (lonafarnib) | Studies (temozolomide) | Trials (temozolomide) | Recent Studies (post-2010) (temozolomide) |
|---|---|---|---|---|---|
| 224 | 34 | 90 | 6,014 | 826 | 4,331 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adema, AD; Honeywell, RJ; Peters, GJ; van der Born, K | 1 |
| Barnes, JW; Chaponis, D; Dellagatta, JL; Fast, E; Greene, ER; Kesari, S; Kieran, MW; Kung, AL; Panagrahy, D; Ramakrishna, N; Sauvageot, C; Stiles, C; Wen, PY | 1 |
| Coan, AD; Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; Peters, KB; Reardon, DA; Threatt, S; Vredenburgh, JJ | 1 |
| Colman, H; Conrad, C; Gilbert, MR; Groves, M; Hsu, S; Kang, S; Levin, V; Liu, D; Liu, V; Puduvalli, V; Yuan, Y; Yung, WK; Yust-Katz, S | 1 |
| Edney, B; Kim, Y; Kondapaneni, RV; Nakod, PS; Rao, SS | 1 |
2 trial(s) available for lonafarnib and temozolomide
| Article | Year |
|---|---|
A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carotenoids; Dacarbazine; Disease-Free Survival; Drug Combinations; Enzyme Inhibitors; Fatty Acids, Unsaturated; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Piperidines; Pyridines; Temozolomide; Vitamin E | 2011 |
Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Piperidines; Pyridines; Supratentorial Neoplasms; Temozolomide | 2013 |
3 other study(ies) available for lonafarnib and temozolomide
| Article | Year |
|---|---|
Cell cycle effects and increased adduct formation by temozolomide enhance the effect of cytotoxic and targeted agents in lung cancer cell lines.
Topics: Animals; Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Dacarbazine; Deoxycytidine; Deoxyguanosine; DNA Adducts; DNA Methylation; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Mice; O(6)-Methylguanine-DNA Methyltransferase; Paclitaxel; Piperidines; Pyridines; Temozolomide | 2009 |
Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Glioma; Humans; Mice; Neoplasm Transplantation; Piperidines; Prenylation; Pyridines; Radiation, Ionizing; ras Proteins; Signal Transduction; Temozolomide; Time Factors | 2011 |
The impact of temozolomide and lonafarnib on the stemness marker expression of glioblastoma cells in multicellular spheroids.
Topics: Cell Line, Tumor; Dibenzocycloheptenes; Drug Resistance, Neoplasm; Endothelial Cells; Glioblastoma; Humans; Nestin; Piperidines; Pyridines; Spheroids, Cellular; Temozolomide; Tumor Microenvironment | 2022 |